[go: up one dir, main page]

NO20015931L - Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin - Google Patents

Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Info

Publication number
NO20015931L
NO20015931L NO20015931A NO20015931A NO20015931L NO 20015931 L NO20015931 L NO 20015931L NO 20015931 A NO20015931 A NO 20015931A NO 20015931 A NO20015931 A NO 20015931A NO 20015931 L NO20015931 L NO 20015931L
Authority
NO
Norway
Prior art keywords
morphine
methods
pharmaceutically acceptable
acceptable salt
pharmaceutical formulations
Prior art date
Application number
NO20015931A
Other languages
English (en)
Other versions
NO20015931D0 (no
Inventor
Charanjit R Behl
Raja G Achari
Jorge C Demeireles
Ramneik Dua
Vincent D Romeo
Anthony P Sileno
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of NO20015931D0 publication Critical patent/NO20015931D0/no
Publication of NO20015931L publication Critical patent/NO20015931L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelse omhandler en farmasøytisk formulering for intranasal administrering som omfatter morfin eller farmasøytisk akseptabelt salt derav, med en pH på fra omkring 3,0 til omkring 7,0. Slike formuleringer tilveiebringer forsterket absorpsjon av morfin eller farmasøytisk akseptabelt salt derav. I en utforming tilveiebringer den foreliggende oppfinnelsen en fremgangsmåte for å utløse en smertestillende- eller anestesirespons i et pattedyr som inkluderer å administrere nasalt en terapeutisk effektiv mengde av morfin eller farmasøytisk akseptabelt salt derav ved en pH på fra omkring 3,0 til omkring 7,0.
NO20015931A 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin NO20015931L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (en) 1999-06-16 2000-05-23 Pharmaceutical formulations and methods comprising intranasal morphine

Publications (2)

Publication Number Publication Date
NO20015931D0 NO20015931D0 (no) 2001-12-04
NO20015931L true NO20015931L (no) 2002-02-08

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015931A NO20015931L (no) 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Country Status (30)

Country Link
US (1) US6677346B1 (no)
EP (2) EP1183027A4 (no)
JP (1) JP2003501467A (no)
KR (1) KR20020016831A (no)
AU (1) AU774175B2 (no)
BG (1) BG106221A (no)
BR (1) BR0012082A (no)
CA (1) CA2374877C (no)
CZ (1) CZ20014399A3 (no)
DE (1) DE10084709T1 (no)
DK (1) DK200101859A (no)
EE (1) EE200100677A (no)
ES (1) ES2197792B1 (no)
FI (1) FI20012462L (no)
GB (1) GB2367005A (no)
HR (1) HRP20010926A2 (no)
HU (1) HUP0201856A3 (no)
IS (1) IS6202A (no)
LT (1) LT4976B (no)
LU (1) LU90859B1 (no)
LV (1) LV12859B (no)
MX (1) MXPA01012879A (no)
NO (1) NO20015931L (no)
NZ (1) NZ515783A (no)
PL (1) PL352556A1 (no)
SE (1) SE0104203L (no)
SI (1) SI20850A (no)
SK (1) SK18172001A3 (no)
TR (1) TR200103613T2 (no)
WO (1) WO2000076506A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
EP1928484B1 (en) * 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
AU2007338210B2 (en) * 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
CN107260672A (zh) 2011-05-13 2017-10-20 欧洲凯尔特公司 包含纳洛酮的鼻内药物剂型
US20150231130A1 (en) 2012-07-26 2015-08-20 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
EP3082817A4 (en) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP7030517B2 (ja) 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
CN115814055A (zh) 2016-04-12 2023-03-21 三叉神经股份公司 含镁催产素制剂和应用方法
EP3528873A2 (en) * 2016-10-21 2019-08-28 Somniferum Labs LLC Apparatus for controlled delivery of opioid and other medications
WO2019076997A1 (en) * 2017-10-20 2019-04-25 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL FORMULATIONS COMPRISING AN OPIOID RECEPTOR AGONIST AS ACTIVE SUBSTANCES, METHODS OF MAKING THEM AND THERAPEUTIC USES THEREOF
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
EP0689438B1 (en) * 1993-03-26 2003-06-04 Franciscus Wilhelmus Henricus Maria Merkus Pharmaceutical compositions for intranasal administration of apomorphine
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
AU714913B2 (en) * 1996-09-27 2000-01-13 Nastech Pharmaceutical Company, Inc. Intranasal formulations for promoting sleep and method of using the same

Also Published As

Publication number Publication date
AU5156100A (en) 2001-01-02
JP2003501467A (ja) 2003-01-14
HUP0201856A1 (en) 2002-09-28
DK200101859A (da) 2001-12-12
HUP0201856A3 (en) 2004-12-28
LT4976B (lt) 2002-12-30
KR20020016831A (ko) 2002-03-06
EP1419774A1 (en) 2004-05-19
SI20850A (sl) 2002-10-31
TR200103613T2 (tr) 2004-08-23
BR0012082A (pt) 2002-05-07
SE0104203D0 (sv) 2001-12-14
ES2197792B1 (es) 2005-05-01
CA2374877A1 (en) 2000-12-21
EP1183027A1 (en) 2002-03-06
LT2001119A (en) 2002-07-25
NZ515783A (en) 2004-05-28
DE10084709T1 (de) 2002-09-26
BG106221A (bg) 2002-08-30
HRP20010926A2 (en) 2003-04-30
ES2197792A1 (es) 2004-01-01
IS6202A (is) 2001-12-14
CZ20014399A3 (cs) 2002-06-12
EP1183027A4 (en) 2003-02-05
FI20012462A7 (fi) 2002-01-16
FI20012462L (fi) 2002-01-16
WO2000076506A1 (en) 2000-12-21
SK18172001A3 (sk) 2002-07-02
SE0104203L (sv) 2001-12-14
GB2367005A (en) 2002-03-27
EE200100677A (et) 2003-02-17
AU774175B2 (en) 2004-06-17
LV12859B (en) 2002-12-20
MXPA01012879A (es) 2003-06-24
US6677346B1 (en) 2004-01-13
LU90859B1 (en) 2002-01-24
GB0128383D0 (en) 2002-01-16
PL352556A1 (en) 2003-08-25
NO20015931D0 (no) 2001-12-04
CA2374877C (en) 2004-04-13

Similar Documents

Publication Publication Date Title
NO20015931L (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
DE69629591D1 (de) Formulierung zur intranasalen verabreichung
MX344036B (es) Composiciones que comprenden azelastina y metodos de uso de la misma.
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
MXPA01012882A (es) Composiciones y metodos que comprenden gluconato de morfina.
DK1039900T3 (da) Farmaceutisk præparat indeholdende sibutramin og orlistat
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
TW200633694A (en) Composition and method for treating asthma
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
GB2426707A (en) A stable parental formulation of levomepromazine and a method for stabilizing said formulation
GB2635282A8 (en) An oral liquid formulation of apixaban
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
EE200300555A (et) Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal
WO2001035946A3 (en) Intranasal administration of raloxifene and tamoxifen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application